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Abstract
Background: Activation of the Wnt/b-catenin signaling pathway plays a crucial role in hepatocellular carcinoma (HCC). Low-
density lipoprotein (LDL) receptor-related protein-6 (LRP6) is one of the co-receptors of the Wnt/b-catenin pathway and
forms a signaling complex with Wnt ligand and Frizzled receptor to activate downstream signaling. However, the role of
LRP6 in hepatocarcinogenesis is unclear. In this study, we examined its expression and roles in human HCC.
Methodology/Principal Findings: Using real-time quantitative RT-PCR, we found that LRP6 was frequently (45%)
overexpressed in human HCCs (P=0.003). In vitro studies showed that ectopic expression of LRP6 increased the protein
level of b-catenin. Moreover, overexpression of the full-length and constitutively active LRP6, respectively, activated the
WNT/b-catenin signaling pathway, as shown by the TCF/b-catenin reporter assay. With regard to the effects of LRP6
overexpression in HCC cells, stable overexpression of the constitutively active LRP6 in BEL-7402 HCC cells enhanced cell
proliferation, cell migration, and invasion in vitro as well as tumorigenicity in nude mice.
Conclusions/Significance: Our findings indicate that overexpression of LRP6 contributes to the hyperactivation of the Wnt/
b-catenin signaling pathway in human HCCs and suggest it may play a role in hepatocarcinogenesis.
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Introduction
Hepatocellular carcinoma (HCC) is the sixth most common
cancer worldwide and particularly prevalent in Eastern and
Southeast Asia and Africa [1]. Aberrant activation of Wnt/b-
catenin signaling pathway is closely associated with the formation
of HCC [2,3,4,5,6,7,8]. Without Wnt ligands, b-catenin is
constantly degraded by a destruction complex containing a
scaffold protein Axin and two kinases GSK3b and CK1.
Mechanistically, b-catenin is phosphorylated by GSK3b and then
ubiquitinated by E3 ligase b-Trcp for degradation. Upon Wnt
activation, b-catenin is no longer targeted for degradation but
accumulates in the cytoplasm and translocates into the nucleus.
Nuclear b-catenin binds TCF transcription factors to initiate the
expression of Wnt target genes, like c-myc and cyclin D1, to
promote cell growth and development. It has been demonstrated
that hyperactivation of this pathway plays an important role in
carcinogenesis and other diseases (for review, see [9,10]).
Accumulation of b-catenin in the cytoplasm and nucleus is the
hallmark of the Wnt-driven carcinogenesis. In our previous study,
we reported that b-catenin gene mutations at exon 3 were found in
about 12% in human HCCs and the mutations at this site
contributed to accumulation of b-catenin in HCC [11]. Interest-
ingly, accumulation of the b-catenin in the cytoplasm was about
62% in HCCs. This suggests that the mechanisms leading to b-
catenin overexpression may be heterogeneous. We hypothesized
that, in addition to b-catenin mutations, hyperactivation of Wnt/
b-catenin pathway may be contributed by other alterations in the
pathway.
Low-density lipoprotein (LDL) receptor-related protein-6
(LRP6) is one of the co-receptors of Wnt/b-catenin pathway
which form a signaling complex with Wnt ligand and Frizzled
receptor to activate downstream signaling. Developmental studies
have shown that co-receptors LRP5/6 are essential for the
activation of Wnt/b-catenin pathway. However, evidence about
the role of LRP6 in tumorigenesis is scanty, with only few reports
showing the potential oncogenic role of LRP6 in cancers. Li et al.
demonstrated that stable expression of LRP6 in human fibrosar-
coma HT1080 cells increased the cytosolic b-catenin level and
enhanced cell proliferation [12]. Two very recent reports by Bu’s
group showed that LRP6 was overexpressed in a subpopulation of
human breast cancers [13] and, more importantly, demonstrated
that activation of the Wnt signaling by overexpressing LRP6 alone
was enough to induce breast cancer formation [14]. These studies
highlighted the importance and possible role of the cell-surface co-
receptor LRP6 level in Wnt-driven carcinogenesis. This may also
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mutations and the proportion of b-catenin accumulation in human
HCCs. Based on this rationale, we hypothesized that overexpres-
sion of the cell surface LRPs contributed to the accumulation of b-
catenin and Wnt-driven hepatocarcinogenesis. This study inves-
tigated the expression pattern of LRP6 and its possible role in
human HCCs.
Our findings showed that LRP6 was significantly up-regulated
in human HCCs. Ectopic expression of constitutively active LRP6
activated Wnt/b-catenin signaling in HCC cells and promoted cell
proliferation, migration and invasion in vitro. LRP6 also enhanced
tumor growth in vivo. Our findings indicate that overexpression of
LRP6 contributes to the hyperactivation of Wnt/b-catenin
signaling pathway and suggest it plays a role in hepatocarcino-
genesis.
Results
Overexpression of LRP6 in human HCCs
The expression pattern of LRP6 has not been reported in
human HCCs. Therefore, we first examined the expression
pattern of LRP6, at both transcript and protein levels, in human
HCC cell lines. Both transcripts and protein of LRP6 were
expressed in all seven HCC cell lines tested (Figure 1A). Then, we
investigated its transcript levels in 60 pairs of human HCCs and
their corresponding non-tumorous livers. The transcript level of
LRP6 was frequently (45%) and significantly up-regulated in
human HCCs, as compared with their corresponding non-
tumorous livers (P=0.003, Mann Whitney test) and normal liver
tissues (P=0.003) (Figure 1B). Cases with T/NT ratio more than 2
folds were defined as overexpression and those with ratio less than
0.5 as underexpression. Twenty-seven (45%) of the 60 cases were
found to have LRP6 overexpression and the range of the T/NT
ratio was from 2.07 to 23.7 folds. In contrast, only 2 cases had T/
NT ratio below 0.5, and 12 cases between 0.5–1.0. We next
performed Western blotting to evaluate the protein levels of LRP6
on 28 pairs of HCCs, randomly selected from these 60 pairs with
mRNA levels examined. Overexpression of LRP6 at protein level
was seen in 9 cases (32%) (Figure 1C). Four of these 9 cases had
upregulation of both LRP6 transcript and protein levels. With
immunohistochemistry, strong positive staining of LRP6 was seen
in the cytoplasm (white arrows) and cell membranes (black short
arrows) of the tumor cells (Figure 1D). Clinicopathological
analysis, however, showed no significant correlation of LRP6
overexpression at mRNA level with any of the clinicopathological
features (Table 1). To examine the relationship between LRP6 and
b-catenin expression, we compared the LRP6 transcript level with
b-catenin using immunohistochemical staining in 36 human HCC
cases. Although 8 (22%) of the cases showed upregulation of both
LRP6 transcript and b-catenin protein levels, there was no
significant association between LRP6 overexpression and b-
catenin overexpression (Table 1).
Transient expression of either full length or constitutively
active form of LRP6 activated the Wnt/b-catenin pathway
To investigate the mechanistic role of LRP6 overexpression on
Wnt/b-catenin pathway, we performed in vitro studies to see
whether Wnt/b-catenin pathway was activated upon ectopic
expression of the LRP6 constructs. Myc-tagged full-length form of
LRP6 (myc-FL LRP6) and its constitutively active form (myc-CA
LRP6) were transiently overexpressed in BEL-7402 HCC cells and
HEK293T cells. The myc-CA LRP6 was a truncated form of
LRP6 protein lacking 4 EGF-like repeats (Figure 2A). It was found
to be a constitutively activated form of LRP6 as demonstrated by
Brown’s group [15]. From the result, the protein levels of b-
catenin were increased upon ectopic expression of either myc-FL
LRP6 or myc-CA LRP6 in both BEL-7402 HCC cell line and
HEK293T cells (Figures 2B).
To investigate the effect of LRP6 overexpression on the
transcriptional activity of Wnt/b-catenin pathway, TCF/b-
catenin reporter assay (TOP/FOP luciferase reporter assay) was
done on both BEL-7402 and HEK293T cells. Our data showed
that overexpression of either myc-FL LRP6 or myc-CA LRP6 led
to an activation of TCF/b-catenin reporter up to ,40 and ,110
folds, respectively, as compared with the vector control (Figure 2C).
Upon Wnt3a treatment, the induction of luciferase signal in myc-
FL LRP6-transfected cells reached ,112-fold, similar to the level
of the cells transfected with the constitutively active form (myc-CA
LRP6) with or without Wnt3a treatment. Similar results were also
observed in HEK293T cells (Figure 2D).
Stable expression of constitutively active form of LRP6
activated Wnt/b-catenin signaling in HCC cells
BEL-7402 cells stably expressing LRP6 were established using
the myc-CA LRP6 construct. After the selection process, four
stable clones of CA LRP6 cells were established. In these myc-CA
LRP6 expressing cells, the protein level of b-catenin was increased
as compared with the parental BEL-7402 cells (Figure 3A). It
indicates that the Wnt/b-catenin signaling pathway was activated
in myc-CA LRP6 expressing BEL-7402 cells.
LRP6 enhanced cell proliferation in vitro
To investigate the role of constitutively active form of LRP6 on
cancer cell growth, the four myc-CA LRP6 stably expressing BEL-
7402 clones and vector control BEL-7402 cells were seeded onto
6-well plates for cell counting. We found that myc-CA LRP6
enhanced the cell proliferation rate of BEL-7402 cells. The cell
numbers on Day 7 in Clones #1, #3, #8, and #11 were
significantly higher than that of the vector control BEL-7402 cells
(P=0.032, ,0.001, =0.002, and 0.005, respectively, Student’s t-
test) (Figure 3B). The doubling time of each clone were also
calculated. The doubling time of vector control, CA LRP6 Clones
#1, #3, #8 and #11 were 1.25, 0.85, 0.99, 0.94 and 0.97 days,
respectively. These data demonstrated that LRP6 expressing cells
had higher proliferative rates than that of the vector control.
LRP6 enhanced both cell migration and invasion in vitro
Cell migration and invasion assays were performed to test
whether the constitutively active form of LRP6 promoted cell
migration and invasion in BEL-7402 HCC cells. Overexpression
of myc-CA LRP6 enhanced cell motility (Figure 4A). The
migrated cells in Clones #3 and #8 were significantly higher in
number than the vector control (P,0.001 for both, Student’s t-
test). In addition, overexpression of myc-CA LRP6 promoted cell
invasion in BEL-7402 cells. The numbers of invaded cells in
Clones #3 and #8 were significantly higher than that of the
vector control BEL-7402 (P,0.001 and =0.009, respectively,
Student’s t-test) (Figure 4B). Similar result was observed in the
other two stable clones, Clones #1 and #11 (Figure S1).
LRP6 enhanced tumor formation in vivo
Our in vitro study demonstrated that myc-CA LRP6 enhanced
cell proliferation of BEL-7402 cells. Here, we investigated its role
on tumorigenicity and tumor growth in nude mice. Two clones of
myc-CA LRP6 and the vector control were injected subcutane-
ously into the flank of the nude mice. The tumors of the two myc-
CA LRP6 stably-expressing tumors were significantly larger than
LRP6 in HCC
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Student’s t-test). In addition, the tumor weight of Clone #3 was
significantly higher as compared with the control vector
(P=0.002, Student’s t-test). Another clone (Clone #8) also showed
a trend of higher tumor weight, although the difference did not
reach statistical significance. Similar results were observed in the
other two stable clones, Clones #1 and #11 (Figure S2).
Discussion
Activation of Wnt/b-catenin signaling pathway is well docu-
mented to be closely associated with carcinogenesis in different
cancers [9,10,18]. In human HCC, mutations of b-catenin, APC
and Axin genes have been found to contribute the activation of
Wnt/b-catenin signaling pathway [19,20,21,22,23]. However, by
frequencies, mutations of the Wnt pathway-related genes in Wnt/
b-catenin signaling alone do not entirely explain the dysregulation
of the pathway. In this cohort of our HCC patients, mutations of
b-catenin at exon 3 was only 11%, while more than 50% of cases
showed hyperactivation b-catenin signaling as reflected by b-
catenin overexpression in immunohistochemical analysis [11]. b-
catenin mutations are not the main cause of dysregulation of Wnt/
b-catenin signaling in our HBV-associated HCCs. Our result is
consistent with that of Hsu et al. also from an area of HBV-
Figure 1. Overexpression of LRP6 in HCC cell lines and human HCCs. (A) Quantitative real-time PCR and Western blotting. Both transcripts
and protein of LRP6 were expressed in all seven HCC cell lines. (B) In human HCCs, the transcript level of LRP6 was frequently (45%) up-regulated as
compared with their corresponding non-tumorous livers (P=0.003). (C) Western blot analysis. LRP6 protein level was determined in 28 HCC pairs and
was found to be overexpressed in 9 (32%) cases. The 9 cases with LRP6 protein overexpression in the tumors are shown. (D) Immunohistochemical
analysis. LRP6 protein was found to be overexpressed in the HCC as compared with the corresponding non-tumorous liver. High power magnification
of the tumor showed strong positive staining of LRP6 protein in the cytoplasm (white arrows) and also the membranes (black short arrows) of the
tumor cells.
doi:10.1371/journal.pone.0036565.g001
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aberrant expression of cell surface Wnt co-receptor LRP6 may
play an important role in the formation of HCC. To our
knowledge, this is the first study to investigate the role of LRP6
and its expression pattern in HCC.
In general, four of our myc-CA LRP6 overexpressing clones
showed more aggressive tumor phenotype in terms of the cell
proliferation, migration, invasion and tumorigenicity assays.
However, among these four stable clones, there was no definite
relationship between their LRP6 expression levels and their b-
catenin levels or aggressive phenotypes. Indeed, clone #3, with the
weakest level of ectopic myc-CA LRP6 expression, showed the
strongest aggressive phenotype as compared with the other clones
with relatively higher protein expression levels of LRP6. This
observation might probably be due to the clonal differences among
those individual clones. Another explanation might be due to the
deleterious effect of high amounts of LRP6 protein leading to the
accumulation of LRP6 intracellular domain (LRP6-ICD) into the
nucleus of stable cells. Indeed, LRP6-ICD was first reported to
increase TCF/b-catenin activity and activate Wnt/b-catenin
pathway [25]. However, further studies showed that it repressed
TCF/b-catenin activity in CHO and HEK 293T cells when it
translocated into the nucleus [26]. This LRP6-ICD was also found
in all of our LRP6 stable clones (data not shown). Therefore, we
speculate that ectopic expression of LRP6 in high levels may lead
to the accumulation of excessive LRP6-ICD protein, which in turn
may act as a negative feedback loop to control the Wnt/b-catenin
signaling. Further investigation on the role of LRP6-ICD and its
mechanism in HCC development is needed.
Cell surface Wnt co-receptor LRP6 was previously found to be
essential for the activation of Wnt/b-catenin signaling upon
binding with Wnt ligands [27,28,29]. Reports on the expression
pattern and functional roles of LRP6 in cancers are scanty. Only
very recently, Liu et al. showed that LRP6 was overexpressed in
20–36% of human breast cancers [13]. In this study, we showed
that both transcript and protein levels of LRP6 were up-regulated
in HCC. Upon ectopic expression of LRP6, the protein level of b-
catenin was increased. Using TCF/b-catenin reporter assay, the b-
catenin-dependent transcriptional activities were also found to be
upregulated in these cell lines. Stable expression of constitutively
active LRP6 in BEL-7402 HCC cells showed hyperactivation of
Wnt/b-catenin pathway with higher level of b-catenin protein.
The findings showed that upregulation of co-receptor LRP6 was
able to increase the activities of Wnt/b-catenin signaling. In
human HCCs, although 22% of cases showed upregulation of
both LRP6 transcript and b-catenin protein levels by immuno-
histochemical staining, there was no significant correlation of
LRP6 overexpression and b-catenin overexpression. It might be
due to the fact that our sample size was small. Furthermore,
overexpression of other Wnt elements, including Fizzled receptors
and Dishevelled proteins, have also been reported to contribute to
upregulate the b-catenin level [17,30,31]. Thus, it may be difficult
to dissect the sole effect of LRP6 upon b-catenin in clinical
samples.
Table 1. Clinicopathologic correlation of LRP6 transcript in HCC patients.
Parameters No LRP6 overexpression LRP6 overexpression ($2-fold) P-value
Gender Male 23 20 0.767
Female 9 6
Age ,60 21 13 0.288
$60 11 13
Tumor stage (TNM) Early (I & II) 12 14 0.290
Advanced (III & IV) 20 12
Tumor size (cm) ,5 cm 8 10 0.388
$5c m 2 3 1 5
Cellular differentiation
(Edmondson grading)
Better differentiation (grades I & II) 14 13 0.590
Poorer differentiation (grades III & IV) 18 11
Tumor encapsulation Absent 21 13 0.278
Present 10 12
Tumor microsatellite Absent 18 13 1.000
Present 14 11
Venous permeation Absent 15 14 0.792
Present 17 12
Non-tumorous liver Non-cirrhotic 21 12 0.280
Cirrhotic 11 13
Serum HBsAg Positive 29 19 0.161
Negative 3 6
b-catenin overexpression Absent 8 11 0.739
By IHC staining* Present 9 8
IHC, immunohistochemical;
*Nuclear stain or cytoplasmic overexpression.
doi:10.1371/journal.pone.0036565.t001
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and invasion in vitro, as well as tumorigenicity in vivo in nude mice.
Our findings support the role of LRP6 in hepatocarcinogenesis. In
fact, similar findings have recently been reported in breast cancer
model by Bu’s group. They showed that either knockdown of
LRP6 or LRP6 antagonist suppressed tumor growth [13]. Using
MMTV-LRP6 mice model, they further confirmed that LRP6
activated Wnt signaling and contributed to breast cancer
tumorigenesis in vivo [14]. By using different experimental
approach, data from our present study and Bu’s group have
concordantly provided evidence that overexpression of cell-surface
Wnt co-receptor LRP6 may play an important role in cancer
Figure 2. Ectopic expression of LRP6 activated the Wnt/b-catenin pathway. (A) Schematic diagram showing the structural domains of Myc-
tagged full length form of LRP6 (myc-FL LRP6) and the constitutively active form (myc-CA LRP6). (B) Western blotting. Myc-FL LRP6 and myc-CA LRP6
were transiently overexpressed in BEL-7402 HCC cell line and human embryonic kidney cell HEK293T cells. The protein level of b-catenin was
increased in both BEL-7402 HCC cell line and HEK293T cells. (C) TOP/FOP luciferase reporter assay. Expression of myc-FL LRP6 led to an activation of
TCF/b-catenin reporter up to ,40-fold (without Wnt3a treatment) and ,120-fold (with Wnt3a treatment), respectively, as compared with the vector
control. The fold of induction in myc-CA LRP6 cells reached ,150-fold even without Wnt3a treatment. (D) Similar results were also observed in
HEK293T cells.
doi:10.1371/journal.pone.0036565.g002
LRP6 in HCC
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pathway.
Evidence supporting the oncogenic role of those cell-surface
Wnt receptors and co-receptors in carcinogenesis is accumulating.
In addition to the aberrant expression of LRP6, overexpression of
other cell surface Wnt receptors or co-receptors has also been
found to play a significant role in the activation of Wnt/b-catenin
pathway in HCC. Frizzled 7 receptor (FZD7) and other Frizzled
receptors have been found to be overexpressed in human HCC
and FZD7 upregulation was associated with activation of Wnt/b-
catenin signaling [30,31,32]. Bengochea et al. assessed the gene
expression profile of 10 Frizzled receptors in human HCC samples
and showed that Frizzled-3/6/7 receptors were up-regulated in
human HCC [33]. Frizzled receptors were also found to be
overexpressed in other cancer types, like gastric and renal
carcinoma and astrocytomas [34,35,36]. All these findings
implicated the potential oncogenic role of the dysregulation of
cell surface Wnt receptors.
In addition to LRP6, co-receptor LRP5 was also found to be
implicated in Wnt/b-catenin pathway in cancers. In fact, both
LRP5 and 6 have been suggested to be oncogenic proteins
and could be a target for cancer therapy [37]. LRP5 was found to
be overexpressed and correlated with tumor metastasis in high-
grade osteosarcoma; blocking the LRP5 by its dominant negative
form decreased tumorigenicity and metastasis of osteosarcoma
[38,39]. Furthermore, internally truncated form of LRP5
(LRP5Delta) has recently been reported to be resistant to DKK1
inhibition and thus contributes to the activation of Wnt/b-
catenin signaling in parathyroid and breast cancer [40,41]. These
reports have revealed the role of LRP5 in oncogenesis. In our
preliminary study, LRP5 was not significantly overexpressed in
human HCCs and the LRP5Delta form was absent in human
Figure 3. Constitutively active LRP6 enhanced cell proliferation in vitro. (A) LRP6 expressing BEL-7402 stable cells were established using
myc-CA LRP6 construct. The protein level of b-catenin was upregulated as compared with the parental BEL-7402 cells. (B) Cell proliferation assay. The
numbers of cells of CA LRP6 Clones #1, #3, #8 and #11 on Day 7 were significantly higher than the vector control BEL-7402 cells (P=0.032, ,0.001,
=0.002 and 0.005, respectively).
doi:10.1371/journal.pone.0036565.g003
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is more likely to have a pathogenic role than LRP5 in human
HCC.
Overall, our findings suggest that overexpression of cell surface
co-receptor LRP6 may contribute to the activation of Wnt/b-
catenin signaling pathway in human HCCs and, in turn, play a
role in hepatocarcinogenesis.
Materials and Methods
Ethics statement
Use of human tissue samples in this project was approved by the
Institutional Review Board of the University of Hong Kong/
Hospital Authority Hong Kong West Cluster. All patients gave
his/her informed and written consent on the use of the clinical
specimens for research. Animal work was preformed following the
Animals (Control of Experiments) Ordinance (Hong Kong) and
Institute’s guidance on animal experiments. The protocol
(CULATR 1132-05) was approved by the Committee on the
Use of Live Animals in Teaching and Research of the University
of Hong Kong.
Patient samples and patients’ demographic data
Sixty pairs of HCCs and their corresponding non-tumorous
liver tissues were employed for real time-quantitative PCR (qPCR)
analysis. Forty-three of the patients were male and 15 were female.
The patients’ ages ranged from 24 to 74 years (mean: 54613
years). The clinicopathological features of the patients are
summarized in Table 1. All patients had surgical resection at
Queen Mary Hospital, The University of Hong Kong and were
randomly selected for this study. The resected specimens were
obtained immediately after surgical resection, snap-frozen in liquid
nitrogen, and kept at 280uC. The non-tumorous liver samples
were taken more than 1 cm away from the tumors.
Plasmid constructs
The full-length (FL) myc-LRP6 pCS2+ and LRP6-EGFP
pCS2+ were generous gifts from Dr. Christof Niehrs (Deutsches
Krebsforschungszentrum, Heidelberg, Germany). Myc-tagged
LRP6 gene was then subcloned into pBABE-puro vector (myc-
FL LRP6); the myc-FL LRP6 construct was digested with BspE1
and SexA1, end-filled and re-ligated to form the truncated myc-
LRP6 without 4 EGF-like repeats. This truncated LRP6 is a
constitutively-active form (myc-CA LRP6) [15]. Super8X Top-
Flash and Super8X Fop-flash reporter constructs were kindly
provided by Dr. Randall Moon (University of Washington, Seattle,
WA).
Cell culture
L cells, L-Wnt3A cells, Human embryonic kidney (HEK293T)
cells, HCC cell lines PLC/PRF/5, HepG2 and Hep3B were
purchased from the American Type Culture Collection (Manassas,
VA). BEL-7402 and SMMC-7721 were obtained from the
Shanghai Institute of Cell Biology. A pair of HCC primary and
metastatic cell lines (H2P and H2M) was kindly provided by Dr.
XY Guan [16]. BEL-7402, SMMC-7721 and HEK293T cells
were maintained in DMEM with high glucose; HepG2, Hep3B
and PLC/PRF/5 cells were maintained in MEM with 1 mM
sodium pyruvate; H2P and H2M cells were maintained in DMEM
with 1 mM sodium pyruvate. All media were supplemented with
10% fetal bovine serum (FBS), penicillin at 100 unit/ml and
streptomycin at 100 mg/ml (Invitrogen, Gaithersburg, MD). All
cells were incubated at 37uC in a humidified incubator containing
5% carbon dioxide.
Preparation of Wnt3A conditioned medium
L or L-Wnt3A cells were grown on 10-cm plates and to 80–
100% confluence. The cells were sub-cultured in a triple-layer
flask filled with around 80 mL of medium. After 4 days, the
culture medium was collected in Falcon tubes and centrifuged to
remove cell debris. The medium was filtered through 0.2-mm
membranes. Fresh medium was replenished and cells were allowed
Figure 4. Constitutively active LRP6 promoted both cell
migration and invasion. Cell migration and invasion assays were
performed using LRP6-stably expressing BEL-7402 cells. (A) Overex-
pression of myc-CA LRP6 enhanced cell migration in BEL-7402 cells. The
numbers of migrated cells in CA LRP6 Clones #3 and #8 were
significantly higher than the vector control (P,0.001 for both). (B)
Overexpression of myc-CA LRP6 promoted cell invasion in BEL-7402
cells. The numbers of invaded cells in CA LRP6 Clones #3 and #8 were
significantly higher than the vector control cells (P,0.001 and =0.009,
respectively).
doi:10.1371/journal.pone.0036565.g004
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medium was collected in Falcon tubes.
Establishment of stable clones
Myc-CA LRP6 stable clones were established to reveal the
functional roles of LRP6 in BEL-7402 cell line. After transfection
of myc-CA LRP6 and vector pBABE-puro, cells were maintained
in 5 mg/ml puromycin and allowed to grow until distinct colonies
were distinguished, at around 4 weeks’ time. Single clones were
isolated and expanded in medium supplemented with 1 mg/ml
puromycin. Each clone was then checked for the overexpression of
the myc-CA LRP6 by Western blotting.
Immunohistochemical staining
Immunohistochemical staining for LRP6 was performed on
formalin-fixed, paraffin-embedded sections using the labeled
streptavidin-biotin method. For antigen retrieval, sections were
immersed in buffer with 1 mM EDTA and boiled for 15 min.
Polyclonal rabbit anti-human LRP6 antibody (Cell signaling,
Danvers, MA) was used at 1:100 dilution. For negative control, the
primary antibody was replaced with Tris-buffered saline.
Western blotting
Total protein from cultured cells was extracted in RIPA lysis
buffer (50 mM, pH 7.4 Tris-HCl, 1% NP-40, 0.25% Na-
Figure 5. Constitutively active LRP6 enhanced tumor cell growth in vivo. (A) In vivo nude mice injection assay was performed by injecting
myc-CA LRP6 stably expressing and vector control BEL-7402 cells subcutaneously into the flank of the nude mice. (B) The tumor sizes of two myc-CA
LRP6 stably expressing tumors were significantly higher as compared with the tumor of vector control (P,0.001). (C) The tumor weight of Clone #3
was higher in myc-CA LRP6 than the control vector (P=0.002). Another clone (Clone #8) showed a trend of higher tumor weight but the difference
did not reach statistical significance (P=0.165). Error bar=SEM.
doi:10.1371/journal.pone.0036565.g005
LRP6 in HCC
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fluoride) with freshly added Complete EDTA-free Protease
Inhibitor Cocktail Tablets (Roche, Mannheim, Germany). Twenty
mg samples were loaded in each lane for SDS-PAGE and then
transferred to polyvinylidene difluoride membrane for immuno-
blotting. Blots were blocked and followed by incubation with
antibodies specific for anti-LRP6 (#2560; Cell signaling), anti-b-
catenin (#610153; BD transduction lab, San Jose, CA), anti-c-
Myc (9E10) (sc-40; Santa Cruz, Santa Cruz, CA) and anti-b-actin
(A5316; Sigma, MO, USA). Blots were then incubated with anti-
mouse or anti-rabbit HRP antibody at 1:5000 dilution (GE
Healthcare Life Sciences, Piscataway, NJ).
Luciferase assay
b-catenin activity was measured by luciferase reporter assay of
TCF/LEF-dependent transcription (TOP/FOP reporter assay).
HCC cells or HEK293 cells were seeded in 24-well plates. Then,
either vector or LRP6 construct was co-transfected with
pSuper8XTOPflash or pSuper8XFOPflash luciferase reporter
construct. Renilla luciferase construct pRL-CMV was also co-
transfected into each well for normalization. The luciferase activity
was measured using the Dual-Luciferase Reporter assay system
(Promega) as described previously [17].
RT-PCR analysis
Total RNA was extracted from HCC cell lines and human HCC
samples by TRIzol reagent (Invitrogen). First-strand cDNA was
synthesized from 1 mg of total RNA using random hexamers with
GeneAmp RNA PCR Kit (Applied Biosystems, Foster City, CA).
The cDNA was then used for detecting the expression level of LRP6
(Hs00233945_m1) with TaqMan Gene Expression Assays (Applied
Biosystems). Quantitative PCR (qPCR) was performed in Applied
Biosystems7900HTFastReal-TimeSystem(AppliedBiosystems)in
triplicates. The expression of target genes in paired HCC and non-
tumorouslivertissuesfromthe samepatientwasexpressedasT/NT
ratio. A T/NT ratio .2 was defined as overexpression, whereas a
T/NT ratio ,0.5 was defined as underexpression.
In vitro proliferation assay
Cell proliferation of LRP6 expressing cells was determined using
cell counter. In brief, 5610
4 of cells were seeded onto 6-well plates
in triplicates for each counting day for 7-day proliferation assay.
Cells were counted on consecutive days for a week and
proliferation curves were plotted.
In vitro cell migration and invasion assays
Cell migration assay was performed using transwell inserts with
polycarbonate membranes of 8.0-mm pore size (Corning Inc., NY).
Matrigel invasion assay was done using transwell insert pre-coated
with Matrigel (BD Biosciences, San Jose, CA). In brief, 1610
5 cells
in serum-free medium were seeded onto the upper chamber.
Culture medium containing 10% FBS was used as a chemoat-
tractant in the lower chamber. Cells were incubated in a
humidified incubator at 37uC for 18 h (for migration assay) or
20 h (for invasion assay). Migrated or invaded cells on the lower
surface of the membrane were then fixed with methanol, stained
with crystal violet, photographed and counted in 5 random fields.
Each experiment was performed thrice.
In vivo tumorigenicity assay
To assess the tumorigenicity, cells were trypsinized and
resuspended in phosphate-buffered saline. Cells (2610
6)w e r e
injected subcutaneously into the flank of 6-week-old male BALB/c
nude mice using a 25-gauge needle (n=5 for each group of
experiments). Tumor size was monitored weekly by measuring the
largest and smallest diameters of tumor and estimated according to
the formula: volume=1/26(largest diameter)6(smallest diameter)
2.
Statistical analysis
The clinicopathologic features of HCC patients were analyzed
by SPSS for Windows 17.0 (SPSS Inc., Chicago, IL). Data from
real-time qPCR were analyzed using Prism 5 software (GraphPad
Software Inc., CA, USA). Mann-Whitney test was used for
analysis between tumor and non-tumor groups, and Student’s t-
test for comparing cell numbers in cell proliferation, migration and
invasion assays. Tests were considered significant if their P values
were less than 0.05.
Supporting Information
Figure S1 Constitutively active LRP6 promoted both
cell migration and invasion. Cell migration and invasion
assays were performed using LRP6-stably expressing BEL-7402
cells. (A) Overexpression of myc-CA LRP6 enhanced cell
migration in BEL-7402 cells. The numbers of migrated cells in
CA LRP6 Clones #1 and #11 (P,0.001 and =0.016,
respectively) were significantly higher than the vector control. (B)
Overexpression of myc-CA LRP6 promoted cell invasion in BEL-
7402 cells. The numbers of invaded cells in CA-LRP6 Clones #1
and #11 were significantly higher than the vector control cells
(P,0.019 and =0.016, respectively).
(TIF)
Figure S2 Constitutively active LRP6 enhanced tumor
cell growth in vivo. (A) In vivo nude mice injection assay was
performed by injecting myc-CA LRP6 stably expressing and
vector control BEL-7402 cells subcutaneously into the flank of the
nude mice. (B) Tumor sizes of two myc-CA LRP6 stably
expressing tumors, Clones #1 and #11, were significantly higher
as compared with the tumor of vector control (P=0.003 and
0.001, respectively). (C) The tumor weights of Clones #1 and #11
showed a trend of higher tumor weight although the difference did
not reach statistical significance (P=0.093 and 0.111, respective-
ly). Error bar=SEM.
(TIF)
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